Clinical and economic evidence thresholds for orphan drugs- Are requirements for favorable health technology assessment and reimbursement on the rise?

Abstract

Authors

A.Y. Shih A. Duong C. Tao J.F. Ransom D.S. Spinner C. White J.J. Doyle E.C. Faulkner